Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ernexa Therapeutics Inc.BTX · Entity 8278 | Director | December 08, 2021 | December 11, 2021 |
| TuHURA Biosciences, Inc./NVDMPI · Entity 6601 | Director | March 30, 2018 | April 03, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ernexa Therapeutics Inc.
Report date December 08, 2021 · Filed December 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.94 · Expires 2031-12-07 | Direct | 67,000 |
Reported balance
After 2021-12-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-12-08 · Grant · Acquired 67,000 · Balance 67,000 F1: A total of 22,336 of the shares subject to the option vest and become exercisable as of 12:01 a.m. Eastern time on the date of the issuer's 2022 Annual Meeting of Stockholders and the remaining 44,664 shares vest and become exercisable in equal monthly installments over the following 24 months, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: A total of 22,336 of the shares subject to the option vest and become exercisable as of 12:01 a.m. Eastern time on the date of the issuer's 2022 Annual Meeting of Stockholders and the remaining 44,664 shares vest and become exercisable in equal monthly installments over the following 24 months, subject to continued service through each vesting date.
TuHURA Biosciences, Inc./NV
Report date March 30, 2018 · Filed April 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,222 |
Reported balance
After 2018-03-30 transaction · row 1
1 source rowRow 1 · 2018-03-30 · Other · Acquired 528 · Balance 8,222 F1: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 08, 2021 Filed Dec 11, 2021 02:00 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option · Derivative | 67,000 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0001140361-21-041285 · form4.xml · derivative · entry 1 Mohr Erich · CIK 0001298170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2031-12-07 F1 · derivative.exercise_date: A total of 22,336 of the shares subject to the option vest and become exercisable as of 12:01 a.m. Eastern time on the date of the issuer's 2022 Annual Meeting of Stockholders and the remaining 44,664 shares vest and become exercisable in equal monthly installments over the following 24 months, subject to continued service through each vesting date. Read SEC document |
| March 30, 2018 Filed Apr 3, 2018 20:07 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 528 | $3.20 | $1,689.60 |
DisclosureSEC source: 0001213900-18-003989 · f4033018mohr_delmar.xml · nonDerivative · entry 1 Mohr Erich · CIK 0001298170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,222 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 21:53 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 528 | $3.20 | $1,689.60 |
DisclosureSEC source: 0000905718-18-000010 · mohr_form4dec312017.xml · nonDerivative · entry 1 Mohr Erich · CIK 0001298170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,694 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 23:51 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 528 | $3.20 | $1,689.60 |
DisclosureSEC source: 0001213900-17-010208 · f4092917mohr_delmarpharm.xml · nonDerivative · entry 1 Mohr Erich · CIK 0001298170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,166 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| July 07, 2017 Filed Jul 12, 2017 01:35 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantPerformance Stock Units · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-17-007478 · f4070717mohr_delmarpharma.xml · derivative · entry 2 Mohr Erich · CIK 0001298170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2022-07-07 F2 · derivative.exercise_price: Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on achievement of specified targets related to the Company's financial performance. F2 · derivative.exercise_date: Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on achievement of specified targets related to the Company's financial performance. Read SEC document |
| July 07, 2017 Filed Jul 12, 2017 01:35 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001213900-17-007478 · f4070717mohr_delmarpharma.xml · derivative · entry 1 Mohr Erich · CIK 0001298170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2027-07-07 F1 · derivative.exercise_date: 12,000 options vest on June 30, 2018, and 3,000 options vest each three months thereafter starting September 30, 2018. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:29 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 528 | $3.20 | $1,689.60 |
DisclosureSEC source: 0001213900-17-007147 · f4063017mohr_delmarpharma.xml · nonDerivative · entry 1 Mohr Erich · CIK 0001298170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,638 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 15:33 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | PurchaseCommon Stock | 4,167 | $3.60 | $15,001.20 |
DisclosureSEC source: 0001213900-17-006884 · f4062617mohr_delmarpharma.xml · nonDerivative · entry 1 Mohr Erich · CIK 0001298170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,110 F1 · price: The Reporting Person purchased the shares in a private transaction for an aggregate purchase price of CDN $20,000. Reported price is based on exchange rate of 0.75. Read SEC document |
| March 31, 2017 Filed Apr 3, 2017 22:15 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 528 | $3.20 | $1,689.60 |
DisclosureSEC source: 0001213900-17-003270 · f4033117mohr_delmar.xml · nonDerivative · entry 1 Mohr Erich · CIK 0001298170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,943 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| December 31, 2016 Filed Jan 3, 2017 18:54 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 528 | $3.20 | $1,689.60 |
DisclosureSEC source: 0001213900-17-000021 · f4123116mohr_delmar.xml · nonDerivative · entry 1 Mohr Erich · CIK 0001298170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,415 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 14:20 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 528 | $3.20 | $1,689.60 |
DisclosureSEC source: 0001213900-16-017291 · f4100316mohr_delmarpharm.xml · nonDerivative · entry 1 Mohr Erich · CIK 0001298170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.